Tina Rashid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tina Rashid has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abi Kanthabalan
Chelsea and Westminster Hospitals, 369 Fulham Rd., London SW10 9NH, UK
1 shared publication - Azure-Dee Pillay
Division of Immunology, University of Cape Town, Cape Town 7935, South Africa
1 shared publication - Carolina Herrera
Affiliation CONRAD, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia, United States of America
1 shared publication - Christian Callebaut
Clinical Virology, Gilead Sciences, Inc., 333 Lakeside Dr, Foster City, 94404 CA, USA
1 shared publication - Feargus Hosking Jervis
Urologistics Ltd., Ipswich IP4 2BF, UK
1 shared publication - James Bellringer
Nuffield Health Parkside Hospital, London SW19 5NX, UK
1 shared publication
Latest Publications
- Open Access
- 14 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2687
PROGRESS (Patient-Reported Outcomes in Genital Reconstructive Surgeries): A Validated Patient-Reported Outcome Measure Questionnaire to Assess Post-Operative Functional Improvement Following Feminising Genital Reconstructive Surgery
Background/Objectives: Our aim was to validate a self-reported patient-reported outcome measure (PROM) questionnaire for use by patients undergoing feminising genital reconstructive surgery (fGRS). Methods: We used the Patient Reported Outcomes in Genital REconstructive SurgerieS (PROGRESS) questionnaire to examine key domains: urinary function, sexual function, cosmetic appearance, bowel function, and general health and wellbeing, which were identified as key components by our experienced surgeons. A reduction in score post-operatively represented an improvement in symptoms. Internal consistency was performed to determine the reliability of the questionnaire. Results: Between 2014 and 2024, 117 patients had completed pre- and post-operative questionnaires by week 52. The overall median score for all domains was 0.37 (interquartile range [IQR] 0.32–0.44) at baseline. At week 52 post-surgery, it was 0.24 (IQR 0.16–0.32), with a median difference (% change in overall score) of −0.12 (−35.8%) (p < 0.001). In all domains apart from bowel function, there was a reduction in scores that achieved statistical significance. There were high Cronbach’s alpha scores at baseline and at week 52 for four out of the five domains: general health and wellbeing a = 0.71 at week 0 and a = 0.79 at week 52; sexual function a = 0.83 at week 0 and a = 0.88 at week 52; cosmetic function a = 0.64 at week 0 and a = 0.84 at week 52; urinary function a = 0.74 at week 0 and a = 0.83 at week 52. Bowel function scored poorly, with a = 0.44 at week 0 and a = 0.49 at week 52. Conclusions: The questionnaire is suitable for use in clinical practice as a standardised way to assess functional outcomes following fGRS.
- 14 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2687
Open AccessPROGRESS (Patient-Reported Outcomes in Genital Reconstructive Surgeries): A Validated Patient-Reported Outcome Measure Questionnaire to Assess Post-Operative Functional Improvement Following Feminising Genital Reconstructive Surgery
Background/Objectives: Our aim was to validate a self-reported patient-reported outcome measure (PROM) questionnaire for use by patients undergoing feminising genital reconstructive surgery (fGRS). Methods: We used the Patient Reported Outcomes in Genital REconstructive SurgerieS (PROGRESS) questionnaire to examine key domains: urinary function, sexual function, cosmetic appearance, bowel function, and general health and wellbeing, which were identified as key components by our experienced surgeons. A reduction in score post-operatively represented an improvement in symptoms. Internal consistency was performed to determine the reliability of the questionnaire. Results: Between 2014 and 2024, 117 patients had completed pre- and post-operative questionnaires by week 52. The overall median score for all domains was 0.37 (interquartile range [IQR] 0.32–0.44) at baseline. At week 52 post-surgery, it was 0.24 (IQR 0.16–0.32), with a median difference (% change in overall score) of −0.12 (−35.8%) (p < 0.001). In all domains apart from bowel function, there was a reduction in scores that achieved statistical significance. There were high Cronbach’s alpha scores at baseline and at week 52 for four out of the five domains: general health and wellbeing a = 0.71 at week 0 and a = 0.79 at week 52; sexual function a = 0.83 at week 0 and a = 0.88 at week 52; cosmetic function a = 0.64 at week 0 and a = 0.84 at week 52; urinary function a = 0.74 at week 0 and a = 0.83 at week 52. Bowel function scored poorly, with a = 0.44 at week 0 and a = 0.49 at week 52. Conclusions: The questionnaire is suitable for use in clinical practice as a standardised way to assess functional outcomes following fGRS.
- Open Access
- 16 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1285
Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
Background: HIV-1 pre-exposure prophylaxis (PrEP) has focused predominantly on protective efficacy in receptive sex, with limited research on the dosing requirements for insertive sex. We pre-clinically assessed the ex vivo pharmacokinetic–pharmacodynamic (PK–PD) profile of tenofovir (TFV) and tenofovir alafenamide (TAF) in foreskin tissue. Methods: Inner and outer foreskin explants were exposed to serial dilutions of TFV or TAF prior to addition of HIV-1BaL at a high (HVT) or a low viral titer (LVT). Infection was assessed by measurement of p24 in foreskin culture supernatants. TFV, TAF and TFV–diphosphate (TFV–DP) concentrations were measured in tissues, culture supernatants and dosing and washing solutions. Results: Dose–response curves were obtained for both drugs, with greater potency observed against LVT. Inhibitory equivalency mimicking oral dosing was defined between 1 mg/mL of TFV and 15 µg/mL of TAF against HVT challenge. Concentrations of TFV–DP in foreskin explants were approximately six-fold higher after ex vivo dosing with TAF than with TFV. Statistically significant negative linear correlations were observed between explant levels of TFV or TFV–DP and p24 concentrations following HVT. Conclusions: Pre-clinical evaluation of TAF in foreskin explants revealed greater potency than TFV against penile HIV transmission. Clinical evaluation is underway to support this finding.
- 16 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1285
Open AccessPre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
Background: HIV-1 pre-exposure prophylaxis (PrEP) has focused predominantly on protective efficacy in receptive sex, with limited research on the dosing requirements for insertive sex. We pre-clinically assessed the ex vivo pharmacokinetic–pharmacodynamic (PK–PD) profile of tenofovir (TFV) and tenofovir alafenamide (TAF) in foreskin tissue. Methods: Inner and outer foreskin explants were exposed to serial dilutions of TFV or TAF prior to addition of HIV-1BaL at a high (HVT) or a low viral titer (LVT). Infection was assessed by measurement of p24 in foreskin culture supernatants. TFV, TAF and TFV–diphosphate (TFV–DP) concentrations were measured in tissues, culture supernatants and dosing and washing solutions. Results: Dose–response curves were obtained for both drugs, with greater potency observed against LVT. Inhibitory equivalency mimicking oral dosing was defined between 1 mg/mL of TFV and 15 µg/mL of TAF against HVT challenge. Concentrations of TFV–DP in foreskin explants were approximately six-fold higher after ex vivo dosing with TAF than with TFV. Statistically significant negative linear correlations were observed between explant levels of TFV or TFV–DP and p24 concentrations following HVT. Conclusions: Pre-clinical evaluation of TAF in foreskin explants revealed greater potency than TFV against penile HIV transmission. Clinical evaluation is underway to support this finding.